You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

neoadjuvant immunochemotherapy

Showing 1 - 25 of 3,011
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neoadjuvant Immunochemotherapy for Lung Cancer

Completed
  • Lung Cancer
  • Neoadjuvant immunochemotherapy
  • Shanghai, Shanghai, China
    Zhencong Chen
Sep 1, 2023

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Recruiting
  • Non-Small Cell Lung Cancer
  • Neoadjuvant immunochemotherapy
  • Neoadjuvant chemotherapy
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital,Chinese Academy of Medica
Aug 1, 2023

Pathological Tumor and Lymph Node Responses After Neoadjuvant

Completed
  • Non Small Cell Lung Cancer
  • +3 more
  • Timing of drug administration
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Nov 24, 2022

HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)

Recruiting
  • HNSCC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Minimally Residual of Esophageal Cancer 001

Recruiting
  • Esophageal Carcinoma
  • Minimal Residual Disease
    • Shijiazhuang, Hebei, China
      Fourth Hospital of Hebei Medical University
    Jul 17, 2023

    Muscle-Invasive Bladder Carcinoma Trial in Philadelphia (AMVAC + Nivolumab)

    Recruiting
    • Muscle-Invasive Bladder Carcinoma
    • AMVAC + Nivolumab
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center - Philadelphia
    Apr 1, 2022

    Esophageal Cancer, Surgery, Neoadjuvant Treatment Trial in Zhengzhou (Neoadjuvant immunochemo)

    Recruiting
    • Esophageal Cancer
    • +3 more
    • Neoadjuvant immunochemotherapy
    • Zhengzhou, Henan, China
      Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzh
    Oct 2, 2022

    Esophagogastric Junction Adenocarcinoma Trial in Guangzhou (Sintilimab)

    Recruiting
    • Esophagogastric Junction Adenocarcinoma
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Dec 29, 2021

    Breast Cancer Trial in Houston (Sacituzumab Govitecan, Pembrolizumab)

    Not yet recruiting
    • Breast Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 22, 2022

    NSCLC Trial in Guangzhou (SBRT, Tislelizumab)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 17, 2022

    Sequence and Time-of-day Infusion of immunoCHemotherapy Affect

    Completed
    • Esophagus Cancer
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Nov 24, 2022

      Immunochemotherapy in Esophageal Cancer

      Recruiting
      • Esophageal Cancer
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Nov 24, 2022

        Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma

        Recruiting
        • Head and Neck Squamous Cell Carcinoma
          • Hangzhou, Zhejiang, China
            Second Affiliated Hospital, School of Medicine, Zhejiang Univers
          Aug 22, 2023

          Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy Trial in Guangzhou (drug, radiation, procedure)

          Recruiting
          • Esophageal Squamous Cell Carcinoma
          • +2 more
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Nov 24, 2022

          Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)

          Not yet recruiting
          • Stage II-IIIB(N2) Non-small Cell Lung Cancer
          • Shanghai, Shanghai, China
            Shanghai Pulmonary Hospital
          Oct 26, 2023

          Neoadjuvent, PD-1 Inhibitor, Chemo Trial in Xi'an (Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin)

          Recruiting
          • Neoadjuvent
          • +3 more
          • Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
          • Xi'an, Shaanxi, China
          • +2 more
          Aug 17, 2023

          NSCLC Trial in Hangzhou (sintilimab, pemetrexed, Carboplatin)

          Active, not recruiting
          • Non-small Cell Lung Cancer
          • sintilimab
          • +3 more
          • Hangzhou, Zhejiang, China
            Second Affiliated Hospital, School of Medicine, Zhejiang Univers
          Jul 11, 2022

          Squamous Cell NSCLC Trial in Hangzhou (Sintilimab, Carboplatin, Albumin-Bound Paclitaxel)

          Not yet recruiting
          • Squamous Cell Non-small Cell Lung Cancer
          • Sintilimab
          • +2 more
          • Hangzhou, Zhejiang, China
            Second Affiliated Hospital, School of Medicine, Zhejiang Univers
          Jun 19, 2022

          NLR and Its Association With Efficacy of Immunochemotherapy in

          Recruiting
          • Esophageal Squamous Cell Carcinoma
          • +2 more
            • Guangzhou, Guangdong, China
              Guangdong Provincial People's Hospital
            Nov 10, 2023

            Esophageal Squamous Cell Carcinoma Trial in Chengdu (Tirelizumab, Paclitaxel, Carboplatin)

            Recruiting
            • Esophageal Squamous Cell Carcinoma
            • Chengdu, Sichuan, China
              Sichuan Cancer Hospital and Research Institute
            Feb 8, 2022

            Tumors, Carcinoma, Squamous, Antineoplastic Agents Trial (Nivolumab Injection [Opdivo])

            Not yet recruiting
            • Neoplasms
            • +2 more
            • Nivolumab Injection [Opdivo]
            • (no location specified)
            Jul 19, 2023

            Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

            Recruiting
            • Esophageal Squamous Cell Carcinoma
              • Shijiazhuang, Hebei, China
                Department of Thoracic Surgery, Fourth Hospital of Hebei Medical
              Oct 25, 2023

              NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB Trial in Heidelberg (Atezolizumab)

              Recruiting
              • NSCLC Stage II
              • +2 more
              • Heidelberg, BaWü, Germany
                Thoraxklinik Heidelberg gGmbH
              Apr 25, 2021

              NSCLC, Esophageal Squamous Cell Carcinoma Trial in Chengdu (Anti-PD-1 antibody combined with Paclitaxel and carboplatin.,

              Recruiting
              • Non-small Cell Lung Cancer
              • Esophageal Squamous Cell Carcinoma
              • Anti-PD-1 antibody combined with Paclitaxel and carboplatin.
              • Surgical treatment stage
              • Chengdu, Sichuan, China
                Sichuan Cancer Hospital
              Sep 5, 2021

              Immunotherapy Trial (Tislelizumab, Capecitabine, oxaliplatin)

              Not yet recruiting
              • Immunotherapy
              • (no location specified)
              Jul 28, 2022